Summary:
In 1,748 adults with T2D (HbA1c 7.5-10.0%) inadequately controlled on basal insulin glargine and metformin, once-weekly semaglutide 1.0 mg for 52 weeks achieved greater HbA1c reduction (1.5% vs 1.2%, P<0.0001), weight loss vs gain (4.1 kg loss vs 2.8 kg gain, difference 7 kg), and more reaching target (<7%: 40.4% vs 30.2%) compared to thrice-daily insulin aspart, with dramatically lower clinically significant hypoglycemia (15.9% vs 43.4%, P<0.0001) but more GI side effects (nausea 14.8% vs 0.8%).
| PICO | Description |
|---|---|
| Population | 1,748 adults with T2D (HbA1c 7.5-10.0%) on basal insulin glargine + metformin, 21 countries. |
| Intervention | Once-weekly semaglutide 1.0 mg added to basal insulin + metformin for 52 weeks. |
| Comparison | Thrice-daily insulin aspart (dose-titrated) added to basal insulin + metformin. |
| Outcome | HbA1c -1.5% vs -1.2%. Weight difference 7 kg. Hypoglycemia 15.9% vs 43.4%. |
SUSTAIN 11: Semaglutide vs Insulin Aspart
RCT · type 2 diabetes · 52 weeks
Once-weekly semaglutide gave greater HbA1c reduction than thrice-daily insulin aspart, with weight loss instead of gain and far less hypoglycemia.
Clinical Context
Many T2D patients require intensification beyond basal insulin. Traditional approach (prandial insulin) is effective but burdensome with hypoglycemia and weight gain.
Clinical Pearls
1. The 7 kg Weight Differential Is Transformative: -4.1 kg vs +2.8 kg profoundly impacts metabolic health.
2. Hypoglycemia Risk Reduction Is Dramatic: Nearly three-fold lower (15.9% vs 43.4%).
3. Glycemic Control Was Superior Despite Simpler Regimen: Once-weekly vs thrice-daily.
4. Cardiovascular Risk Factors Favored Semaglutide: SBP reduced 3.0 mmHg vs increased 0.9 mmHg.
Practical Application
Consider semaglutide as first-line intensification for most patients on basal insulin. Monitor for hypoglycemia and reduce basal insulin as needed.
Study Limitations
Open-label design. 52-week duration. Cost and access barriers to GLP-1 RAs.
Bottom Line
Semaglutide is superior to prandial insulin aspart for basal insulin intensification with better control, 7 kg weight advantage, and dramatic hypoglycemia reduction.
Source: Kellerer M, et al. “Semaglutide vs Insulin Aspart Added to Basal Insulin in T2D (SUSTAIN 11).” Diabetes Obes Metab, 2022. Read article